BDB-001 Phase III Trial in ANCA-Associated Vasculitis

Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2025
The primary aim is to study the efficacy of treatment with BDB-001 Injection to induce remission in patients with active anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), when used in combination with cyclophosphamide followed by azathioprine, or in combination with rituximab
Epistemonikos ID: b6385b417aba650050b20961c4d1f35763d54c0c
First added on: Sep 12, 2025